Substance
ID:349105
Names and Identifiers
IUPAC Traditional name
(-)-malic acid; sunitinib
Synonyms
SU 11248SU112248Sunitinib malateSU 011248N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt
IUPAC name
(2S)-2-hydroxybutanedioic acid; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Properties
Safety Information
MSDS Link
Risk Statements
61-2-48/25
GHS Pictograms
Respiratory sensitization, category 1
Germ cell mutagenicity, categories 1A,1B,2
Carcinogenicity, categories 1A,1B,2
Reproductive toxicity, categories 1A,1B,2
Specific Target Organ Toxicity – Single exposure, categories 1,2
Specific Target Organ Toxicity – Repeated exposure, categories 1,2
Aspiration Hazard, category 1
Storage Temperature
room temp
European Hazard Symbols
Toxic (T)GHS Hazard statements
H360-H372
GHS Precautionary statements
P201-P308+P313
German water hazard class
2
GHS Signal Word
Danger
Safety Statements
53-22-36/37
Product Information
Empirical Formula (Hill Notation)
C22H27FN4O2 · C4H6O5
Purity
≥98% (HPLC)
Physical Property
Solubility
DMSO: >10 mg/mL
Apperance
powder
Molecule Details
Biochem/physiol Actions
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug.
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug.
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data